These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38913608)

  • 1. Dietary intervention rescues a bone porosity phenotype in a murine model of Neurofibromatosis Type 1 (NF1).
    O'Donohue AK; Li XC; Lee LR; Vasiljevski ER; Little DG; Munns CF; Schindeler A
    PLoS One; 2024; 19(6):e0304778. PubMed ID: 38913608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary intervention rescues myopathy associated with neurofibromatosis type 1.
    Summers MA; Rupasinghe T; Vasiljevski ER; Evesson FJ; Mikulec K; Peacock L; Quinlan KG; Cooper ST; Roessner U; Stevenson DA; Little DG; Schindeler A
    Hum Mol Genet; 2018 Feb; 27(4):577-588. PubMed ID: 29228356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1).
    Vasiljevski ER; Houweling PJ; Rupasinghe T; Kaur T; Summers MA; Roessner U; Little DG; Schindeler A
    PLoS One; 2020; 15(8):e0237097. PubMed ID: 32810864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF1 is a critical regulator of muscle development and metabolism.
    Sullivan K; El-Hoss J; Quinlan KG; Deo N; Garton F; Seto JT; Gdalevitch M; Turner N; Cooney GJ; Kolanczyk M; North KN; Little DG; Schindeler A
    Hum Mol Genet; 2014 Mar; 23(5):1250-9. PubMed ID: 24163128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.
    Kühnisch J; Seto J; Lange C; Schrof S; Stumpp S; Kobus K; Grohmann J; Kossler N; Varga P; Osswald M; Emmerich D; Tinschert S; Thielemann F; Duda G; Seifert W; El Khassawna T; Stevenson DA; Elefteriou F; Kornak U; Raum K; Fratzl P; Mundlos S; Kolanczyk M
    PLoS One; 2014; 9(1):e86115. PubMed ID: 24465906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
    Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
    Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse.
    Summers MA; Vasiljevski ER; Mikulec K; Peacock L; Little DG; Schindeler A
    Mol Genet Metab; 2018 Apr; 123(4):518-525. PubMed ID: 29477258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With Osteomalacia-like Bone Phenotype.
    Kamiya N; Yamaguchi R; Aruwajoye O; Kim AJ; Kuroyanagi G; Phipps M; Adapala NS; Feng JQ; Kim HK
    J Bone Miner Res; 2017 Aug; 32(8):1716-1726. PubMed ID: 28425622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromin inactivation impairs osteocyte development in Nf1Prx1 and Nf1Col1 mouse models.
    Kühnisch J; Seto J; Lange C; Stumpp S; Kobus K; Grohmann J; Elefteriou F; Fratzl P; Mundlos S; Kolanczyk M
    Bone; 2014 Sep; 66():155-62. PubMed ID: 24947449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic characterization of transgenic mice harboring Nf1+/- or Nf1-/- osteoclasts in otherwise Nf1+/+ background.
    Alanne MH; Siljamäki E; Peltonen S; Väänänen K; Windle JJ; Parada LF; Määttä JA; Peltonen J
    J Cell Biochem; 2012 Jun; 113(6):2136-46. PubMed ID: 22307743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient.
    Kobus K; Hartl D; Ott CE; Osswald M; Huebner A; von der Hagen M; Emmerich D; Kühnisch J; Morreau H; Hes FJ; Mautner VF; Harder A; Tinschert S; Mundlos S; Kolanczyk M
    PLoS One; 2015; 10(3):e0119030. PubMed ID: 25775093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.
    Vasiljevski ER; Burns J; Bray P; Donlevy G; Mudge AJ; Jones KJ; Summers MA; Biggin A; Munns CF; McKay MJ; Baldwin JN; Little DG; Schindeler A
    Am J Med Genet A; 2021 Oct; 185(10):2976-2985. PubMed ID: 34155781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease).
    Petramala L; Giustini S; Zinnamosca L; Marinelli C; Colangelo L; Cilenti G; Formicuccia MC; D'Erasmo E; Calvieri S; Letizia C
    Arch Dermatol Res; 2012 May; 304(4):325-31. PubMed ID: 22120694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
    Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
    J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
    El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
    J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
    Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
    Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).
    Schindeler A; Little DG
    Bone; 2008 Apr; 42(4):616-22. PubMed ID: 18248783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing bone formation in posterior spine fusion using rhBMP-2 and zoledronic acid in wild type and NF1 deficient mice.
    Bobyn J; Rasch A; Kathy M; Little DG; Schindeler A
    J Orthop Res; 2014 Aug; 32(8):1090-4. PubMed ID: 24719295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
    Yang FC; Chen S; Robling AG; Yu X; Nebesio TD; Yan J; Morgan T; Li X; Yuan J; Hock J; Ingram DA; Clapp DW
    J Clin Invest; 2006 Nov; 116(11):2880-91. PubMed ID: 17053831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.
    Li H; Liu Y; Zhang Q; Jing Y; Chen S; Song Z; Yan J; Li Y; Wu X; Zhang X; Zhang Y; Case J; Yu M; Ingram DA; Yang FC
    Pediatr Res; 2009 Jun; 65(6):613-8. PubMed ID: 19247213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.